Graham Dixon joins Galapagos as Chief Scientific Officer

About Galapagos Genomics NV
Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer’s disease and asthma.  Proprietary targets and compounds resulting from Galapagos’ programs are both developed internally and selectively out-licensed.  Galádeno, Galapagos’ services unit, provides reagents and functional screens to leading pharmaceutical, biotech and nutraceutical companies for rapid identification and validation of novel drug targets. Galapagos currently employs 70 people, including 22 PhD’s, and occupies a discovery research facility in Mechelen, Belgium, and a reagent and services business unit in Leiden, The Netherlands.  Partners include Bayer, Boehringer Ingelheim,  Celgene, Johnson & Johnson, Pfizer, Procter & Gamble, Vertex and Wyeth.  Galapagos was founded in 1999 by Crucell (Nasdaq, Euronext: CRXL) and Tibotec to exploit Crucell’s unique PER.C6® technology for target discovery.  The shareholders include Abingworth, Apax, Burrill, AlpInvest, Crucell and Tibotec-Virco.
More information about Galapagos can be found at